Results 51 to 60 of about 115,328 (341)

Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study [PDF]

, 2018
Introduction: The management of bisphosphonate-related osteonecrosis of the jaw (BRONJ), with no evidence-based guidelines, remains controversial. We aimed to evaluate the efficiency of a conservative surgical treatment combining Er,Cr:YSGG laser and ...
Albanese, Antonino, Bedogni, Alberto, Campisi, Giuseppina, Cumbo, Enzo Maria Giuseppe, Di Fede, Olga, Licata, Maria Ester, Maniscalco, Laura, Mauceri, Rodolfo, Mazzola, Giuseppina, Panzarella, Vera, Toia, Francesca   +10 more
core   +1 more source

Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.

Journal of Clinical Endocrinology and Metabolism, 2018
CONTEXT It is uncertain which osteoporosis therapy is more effective: bisphosphonates or denosumab. OBJECTIVE To determine whether denosumab therapy increases bone mineral density (BMD) and reduces fracture risk more so than bisphosphonates in patients
H. Lyu, B. Jundi, Chang Xu, S. Tedeschi, K. Yoshida, S. Zhao, Sagar U. Nigwekar, B. Leder, D. Solomon   +8 more
semanticscholar   +1 more source

Investigating the efficacy of bisphosphonates treatment against multiple myeloma induced bone disease using a computational model [PDF]

, 2014
Multiple myeloma (MM)-induced bone disease is mortal for most MM patients. Bisphosphonates are first-line treatment for MM-induced bone disease, since it can inhibit osteoclast activity and the resultant bone resorption by suppressing the differentiation
Fagan, Michael J., Genever, Paul G., Ji, Bing, Yang, Qing   +3 more
core   +1 more source

Role of Prednisone and 25(OH) Vitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus

Arthritis Care &Research, Accepted Article.
Objective We evaluated the role of 25‐hydroxy vitamin D, prednisone and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25‐hydroxy vitamin D [25(OH)D] levels and other potential risk factors with BMD measures (spine T‐scores) and osteoporosis ...
Nima Madanchi, Andrea Fava, Daniel W Goldman, Laurence S Magder, Michelle Petri   +4 more
wiley   +1 more source

Coping with complexity: working beyond the guidelines for patients with multimorbidities [PDF]

, 2015
Primary care physicians believe they are delivering evidence-based care, understanding that adherence to evidence-based clinical guidelines results in tangible benefits in the populations for which they were developed.
Treadwell, Julian
core   +3 more sources

Vibration‐Mediated Recovery of Irradiated Osteocytes and Their Regulatory Role in Breast Cancer Bone Metastasis

Advanced Healthcare Materials, EarlyView.
Radiotherapy damages bone and disrupts osteocyte function, yet mechanically mediated protection remains largely unexplored. This study demonstrates that low‐magnitude, high‐frequency (LMHF) vibration mitigates irradiated osteocyte apoptosis, restores their ability to regulate breast cancer extravasation, and acts synergistically with radiotherapy to ...
Xin Song, Kimberly Seaman, Amel Sassi, Chun‐Yu Lin, Tiankuo Chu, Liyun Wang, Yu Sun, Lidan You   +7 more
wiley   +1 more source

Patient level pooled analysis of 68,500 patients from seven major vitamin D fracture trials in the US and Europe [PDF]

, 2010
Objectives To identify participants’ characteristics that influence the anti-fracture efficacy of vitamin D or vitamin D plus calcium with respect to any fracture, hip fracture, and clinical vertebral fracture and to assess the influence of dosing ...
Abrahamsen, B, Anderson, F, Avenell, A, Brixen, K, Cooper, C, F, Hutchison, Francis, R M, Jackson, R, Johansen, A, LaCroix, A Z, Masud, T, Meyer, H E, Mosekilde, L, Rejnmark, L, Robbins, J A, Smith, H, The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group, Torgerson, D, Wactawski-Wende, J   +18 more
core   +2 more sources

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

Journal of Clinical Endocrinology and Metabolism, 2016
Context: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. Objective: The objective of the study was to compare the effect of transitioning from oral bisphosphonates to denosumab or ZOL on bone mineral density (
P. Miller, N. Pannacciulli, Jacques P. Brown, E. Czerwiński, B. Nedergaard, M. Bolognese, J. Malouf, H. Bone, J. Reginster, A. Singer, C. Wang, R. Wagman, S. Cummings   +12 more
semanticscholar   +1 more source

Increased Anti‐Psoriatic Effect of Anti‐Inflammatory Dendrimers Using Fluid Catanionic Vesicle‐Based Topical Formulations

Advanced Healthcare Materials, EarlyView.
Next‐Generation Psoriasis Therapy – With advanced dendrimer‐based formulations, this study paves the way for highly effective, skin‐permeable treatments. Encapsulated in fluid catanionic vesicles, IMD‐006 and its analogues show promising anti‐psoriatic effects offering a targeted, non‐invasive approach to managing chronic skin inflammation.
Ranime Jebbawi, Abdelouahd Oukhrib, Emily Clement, Hélène Labie, Stéphanie Cassel, Séverine Fruchon, Anne‐Marie Caminade, Michel Simon, Rémy Poupot, Cédric‐Olivier Turrin, Muriel Blanzat   +10 more
wiley   +1 more source

American Society of Clinical Oncology recommendations of Bisphosphonates administration and bone health issues in women with breast cancer. Part 1. Recommendations on Bisphosphonates use in the treatment of patients with breast cancer.

Опухоли женской репродуктивной системы, 2014
American Society of Clinical Oncology recommendations of Bisphosphonates administration and bone health issues in women with breast cancer.Part 1. Recommendations on Bisphosphonates use in the treatment of patients with breast cancer.
I. V. Vysotskaya
doaj   +1 more source